{"id":34809,"date":"2025-08-05T10:31:33","date_gmt":"2025-08-05T08:31:33","guid":{"rendered":"https:\/\/ggba.swiss\/oculis-secures-up-to-chf-100-million-in-expanded-loan-facility-with-blackrock\/"},"modified":"2025-08-05T10:34:09","modified_gmt":"2025-08-05T08:34:09","slug":"oculis-obtient-jusqua-chf-100-millions-dans-le-cadre-dun-pret-avec-blackrock","status":"publish","type":"post","link":"https:\/\/ggba.swiss\/fr\/oculis-obtient-jusqua-chf-100-millions-dans-le-cadre-dun-pret-avec-blackrock\/","title":{"rendered":"Oculis obtient jusqu\u2019\u00e0 CHF 100 millions dans le cadre d\u2019un pr\u00eat avec BlackRock"},"content":{"rendered":"\n<p>La soci\u00e9t\u00e9 biopharmaceutique vaudoise Oculis a annonc\u00e9 un avenant \u00e0 son accord de pr\u00eat avec BlackRock, portant sa capacit\u00e9 d\u2019emprunt de CHF 75 \u00e0 100 millions. Cette structure \u00e9tendue prolonge l\u2019horizon financier de l\u2019entreprise jusqu\u2019au d\u00e9but de 2028, tout en soutenant le d\u00e9veloppement de ses traitements ophtalmiques et neuroprotecteurs en phase avanc\u00e9e.<\/p>\n\n\n\n<p>L\u2019accord r\u00e9vis\u00e9 remplace celui sign\u00e9 en mai 2024 et comprend trois tranches de 25 millions de francs chacune, ainsi qu\u2019une tranche optionnelle de 25 millions suppl\u00e9mentaires, accord\u00e9e sur des bases mutuellement convenues. Aucun montant n\u2019a \u00e9t\u00e9 tir\u00e9 lors de la signature, mais la structure offre \u00e0 Oculis une flexibilit\u00e9 renforc\u00e9e \u00e0 l\u2019approche de jalons cliniques et r\u00e9glementaires importants.<\/p>\n\n\n\n<p>L\u2019entreprise fait progresser trois candidats principaux :<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>OCS-01, un collyre pour l\u2019\u0153d\u00e8me maculaire diab\u00e9tique, actuellement en essai de phase 3 (\u00e9tudes DIAMOND). Les premiers r\u00e9sultats sont attendus au deuxi\u00e8me trimestre 2026, avec un possible d\u00e9p\u00f4t de demande d\u2019autorisation dans la foul\u00e9e.<\/li>\n\n\n\n<li>Privosegtor (OCS-05), une th\u00e9rapie neuroprotectrice, fait l\u2019objet de discussions r\u00e9glementaires pour trois indications : n\u00e9vrite optique aigu\u00eb, neuropathie optique isch\u00e9mique ant\u00e9rieure non art\u00e9ritique (NAION), et pouss\u00e9es aigu\u00ebs de scl\u00e9rose en plaques.<\/li>\n\n\n\n<li>Licaminlimab (OCS-02), un collyre anti-TNF\u03b1 pour le traitement de la s\u00e9cheresse oculaire, d\u00e9butera ses essais de phase 2\/3 au second semestre 2025.<\/li>\n<\/ul>\n\n\n\n<p>\u00ab Notre solide position de tr\u00e9sorerie actuelle nous donne une visibilit\u00e9 jusqu\u2019au d\u00e9but de 2028, visibilit\u00e9 encore renforc\u00e9e par cette facilit\u00e9 de pr\u00eat, alors que nous poursuivons le d\u00e9veloppement de notre portefeuille de solutions diff\u00e9renci\u00e9es \u00bb, a d\u00e9clar\u00e9 Riad Sherif, M.D., CEO d\u2019Oculis.<\/p>\n\n\n\n<p>Ce d\u00e9veloppement financier s\u2019ajoute \u00e0 deux lev\u00e9es de fonds majeures r\u00e9alis\u00e9es au cours des 18 derniers mois : <a href=\"https:\/\/ggba.swiss\/fr\/oculis-realise-une-offre-directe-enregistree-sursouscrite-de-usd-59-millions\/\">un placement priv\u00e9 de USD 59 millions en avril 2024<\/a>, puis <a href=\"https:\/\/ggba.swiss\/fr\/oculis-leve-usd-100-millions-pour-ses-traitements-neuro-ophtalmiques\/\">une lev\u00e9e sursouscrite de USD 100 millions en f\u00e9vrier 2025<\/a>. Ces op\u00e9rations t\u00e9moignent de la confiance soutenue des investisseurs dans le pipeline clinique et la strat\u00e9gie d\u2019Oculis.<\/p>\n\n\n\n<p>Bas\u00e9e \u00e0 Lausanne, la soci\u00e9t\u00e9 est cot\u00e9e en bourse et doublement list\u00e9e sur le NASDAQ am\u00e9ricain et le NASDAQ Islande.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Oculis renforce sa facilit\u00e9 de pr\u00eat avec BlackRock jusqu\u2019\u00e0 CHF 100 millions, prolongeant sa visibilit\u00e9 financi\u00e8re et soutenant ses essais cliniques avanc\u00e9s.<\/p>\n","protected":false},"author":6,"featured_media":34806,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"mc4wp_mailchimp_campaign":[],"footnotes":""},"categories":[843],"tags":[1169,1148,1141],"class_list":["post-34809","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-sciences-de-la-vie","tag-biotech-fr-2","tag-financing-fr-2","tag-personalized-medicine-fr-2"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Oculis obtient jusqu\u2019\u00e0 CHF 100 millions dans le cadre d&#039;un pr\u00eat<\/title>\n<meta name=\"description\" content=\"Oculis renforce sa facilit\u00e9 de pr\u00eat jusqu\u2019\u00e0 CHF 100 millions, prolongeant sa visibilit\u00e9 financi\u00e8re et soutenant ses essais cliniques avanc\u00e9s.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ggba.swiss\/fr\/oculis-obtient-jusqua-chf-100-millions-dans-le-cadre-dun-pret-avec-blackrock\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Oculis obtient jusqu\u2019\u00e0 CHF 100 millions dans le cadre d&#039;un pr\u00eat\" \/>\n<meta property=\"og:description\" content=\"Oculis renforce sa facilit\u00e9 de pr\u00eat jusqu\u2019\u00e0 CHF 100 millions, prolongeant sa visibilit\u00e9 financi\u00e8re et soutenant ses essais cliniques avanc\u00e9s.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ggba.swiss\/fr\/oculis-obtient-jusqua-chf-100-millions-dans-le-cadre-dun-pret-avec-blackrock\/\" \/>\n<meta property=\"og:site_name\" content=\"Greater Geneva Bern area\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-05T08:31:33+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-08-05T08:34:09+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ggba.swiss\/app\/uploads\/2025\/08\/Oculis-Eye-Care-1180x811-1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1180\" \/>\n\t<meta property=\"og:image:height\" content=\"811\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Pierre-Yves Oehrli\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Pierre-Yves Oehrli\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/ggba.swiss\/fr\/oculis-obtient-jusqua-chf-100-millions-dans-le-cadre-dun-pret-avec-blackrock\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/oculis-obtient-jusqua-chf-100-millions-dans-le-cadre-dun-pret-avec-blackrock\/\"},\"author\":{\"name\":\"Pierre-Yves Oehrli\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\"},\"headline\":\"Oculis obtient jusqu\u2019\u00e0 CHF 100 millions dans le cadre d\u2019un pr\u00eat avec BlackRock\",\"datePublished\":\"2025-08-05T08:31:33+00:00\",\"dateModified\":\"2025-08-05T08:34:09+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/oculis-obtient-jusqua-chf-100-millions-dans-le-cadre-dun-pret-avec-blackrock\/\"},\"wordCount\":377,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/oculis-obtient-jusqua-chf-100-millions-dans-le-cadre-dun-pret-avec-blackrock\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2025\/08\/Oculis-Eye-Care-1180x811-1.jpg\",\"keywords\":[\"Biotech\",\"Financing\",\"Personalized Medicine\"],\"articleSection\":[\"Sciences de la vie\"],\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/ggba.swiss\/fr\/oculis-obtient-jusqua-chf-100-millions-dans-le-cadre-dun-pret-avec-blackrock\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/ggba.swiss\/fr\/oculis-obtient-jusqua-chf-100-millions-dans-le-cadre-dun-pret-avec-blackrock\/\",\"url\":\"https:\/\/ggba.swiss\/fr\/oculis-obtient-jusqua-chf-100-millions-dans-le-cadre-dun-pret-avec-blackrock\/\",\"name\":\"Oculis obtient jusqu\u2019\u00e0 CHF 100 millions dans le cadre d'un pr\u00eat\",\"isPartOf\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/oculis-obtient-jusqua-chf-100-millions-dans-le-cadre-dun-pret-avec-blackrock\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/oculis-obtient-jusqua-chf-100-millions-dans-le-cadre-dun-pret-avec-blackrock\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2025\/08\/Oculis-Eye-Care-1180x811-1.jpg\",\"datePublished\":\"2025-08-05T08:31:33+00:00\",\"dateModified\":\"2025-08-05T08:34:09+00:00\",\"author\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\"},\"description\":\"Oculis renforce sa facilit\u00e9 de pr\u00eat jusqu\u2019\u00e0 CHF 100 millions, prolongeant sa visibilit\u00e9 financi\u00e8re et soutenant ses essais cliniques avanc\u00e9s.\",\"breadcrumb\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/oculis-obtient-jusqua-chf-100-millions-dans-le-cadre-dun-pret-avec-blackrock\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ggba.swiss\/fr\/oculis-obtient-jusqua-chf-100-millions-dans-le-cadre-dun-pret-avec-blackrock\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/ggba.swiss\/fr\/oculis-obtient-jusqua-chf-100-millions-dans-le-cadre-dun-pret-avec-blackrock\/#primaryimage\",\"url\":\"https:\/\/ggba.swiss\/app\/uploads\/2025\/08\/Oculis-Eye-Care-1180x811-1.jpg\",\"contentUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2025\/08\/Oculis-Eye-Care-1180x811-1.jpg\",\"width\":1180,\"height\":811,\"caption\":\"Le portefeuille de produits d\u2019Oculis propose des th\u00e9rapies non invasives et transformatrices aux patients souffrant de pathologies ophtalmiques et neuro-ophtalmiques pour lesquelles les options de traitement sont limit\u00e9es.\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ggba.swiss\/fr\/oculis-obtient-jusqua-chf-100-millions-dans-le-cadre-dun-pret-avec-blackrock\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ggba.swiss\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Oculis obtient jusqu\u2019\u00e0 CHF 100 millions dans le cadre d\u2019un pr\u00eat avec BlackRock\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\",\"url\":\"https:\/\/staging.ggba.swiss\/en\/\",\"name\":\"Greater Geneva Bern area\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\",\"name\":\"Pierre-Yves Oehrli\",\"url\":\"https:\/\/ggba.swiss\/fr\/author\/pierre-yves-oehrli\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Oculis obtient jusqu\u2019\u00e0 CHF 100 millions dans le cadre d'un pr\u00eat","description":"Oculis renforce sa facilit\u00e9 de pr\u00eat jusqu\u2019\u00e0 CHF 100 millions, prolongeant sa visibilit\u00e9 financi\u00e8re et soutenant ses essais cliniques avanc\u00e9s.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ggba.swiss\/fr\/oculis-obtient-jusqua-chf-100-millions-dans-le-cadre-dun-pret-avec-blackrock\/","og_locale":"fr_FR","og_type":"article","og_title":"Oculis obtient jusqu\u2019\u00e0 CHF 100 millions dans le cadre d'un pr\u00eat","og_description":"Oculis renforce sa facilit\u00e9 de pr\u00eat jusqu\u2019\u00e0 CHF 100 millions, prolongeant sa visibilit\u00e9 financi\u00e8re et soutenant ses essais cliniques avanc\u00e9s.","og_url":"https:\/\/ggba.swiss\/fr\/oculis-obtient-jusqua-chf-100-millions-dans-le-cadre-dun-pret-avec-blackrock\/","og_site_name":"Greater Geneva Bern area","article_published_time":"2025-08-05T08:31:33+00:00","article_modified_time":"2025-08-05T08:34:09+00:00","og_image":[{"width":1180,"height":811,"url":"https:\/\/ggba.swiss\/app\/uploads\/2025\/08\/Oculis-Eye-Care-1180x811-1.jpg","type":"image\/jpeg"}],"author":"Pierre-Yves Oehrli","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"Pierre-Yves Oehrli","Dur\u00e9e de lecture estim\u00e9e":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ggba.swiss\/fr\/oculis-obtient-jusqua-chf-100-millions-dans-le-cadre-dun-pret-avec-blackrock\/#article","isPartOf":{"@id":"https:\/\/ggba.swiss\/fr\/oculis-obtient-jusqua-chf-100-millions-dans-le-cadre-dun-pret-avec-blackrock\/"},"author":{"name":"Pierre-Yves Oehrli","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"headline":"Oculis obtient jusqu\u2019\u00e0 CHF 100 millions dans le cadre d\u2019un pr\u00eat avec BlackRock","datePublished":"2025-08-05T08:31:33+00:00","dateModified":"2025-08-05T08:34:09+00:00","mainEntityOfPage":{"@id":"https:\/\/ggba.swiss\/fr\/oculis-obtient-jusqua-chf-100-millions-dans-le-cadre-dun-pret-avec-blackrock\/"},"wordCount":377,"commentCount":0,"image":{"@id":"https:\/\/ggba.swiss\/fr\/oculis-obtient-jusqua-chf-100-millions-dans-le-cadre-dun-pret-avec-blackrock\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2025\/08\/Oculis-Eye-Care-1180x811-1.jpg","keywords":["Biotech","Financing","Personalized Medicine"],"articleSection":["Sciences de la vie"],"inLanguage":"fr-FR","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/ggba.swiss\/fr\/oculis-obtient-jusqua-chf-100-millions-dans-le-cadre-dun-pret-avec-blackrock\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/ggba.swiss\/fr\/oculis-obtient-jusqua-chf-100-millions-dans-le-cadre-dun-pret-avec-blackrock\/","url":"https:\/\/ggba.swiss\/fr\/oculis-obtient-jusqua-chf-100-millions-dans-le-cadre-dun-pret-avec-blackrock\/","name":"Oculis obtient jusqu\u2019\u00e0 CHF 100 millions dans le cadre d'un pr\u00eat","isPartOf":{"@id":"https:\/\/staging.ggba.swiss\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ggba.swiss\/fr\/oculis-obtient-jusqua-chf-100-millions-dans-le-cadre-dun-pret-avec-blackrock\/#primaryimage"},"image":{"@id":"https:\/\/ggba.swiss\/fr\/oculis-obtient-jusqua-chf-100-millions-dans-le-cadre-dun-pret-avec-blackrock\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2025\/08\/Oculis-Eye-Care-1180x811-1.jpg","datePublished":"2025-08-05T08:31:33+00:00","dateModified":"2025-08-05T08:34:09+00:00","author":{"@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"description":"Oculis renforce sa facilit\u00e9 de pr\u00eat jusqu\u2019\u00e0 CHF 100 millions, prolongeant sa visibilit\u00e9 financi\u00e8re et soutenant ses essais cliniques avanc\u00e9s.","breadcrumb":{"@id":"https:\/\/ggba.swiss\/fr\/oculis-obtient-jusqua-chf-100-millions-dans-le-cadre-dun-pret-avec-blackrock\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ggba.swiss\/fr\/oculis-obtient-jusqua-chf-100-millions-dans-le-cadre-dun-pret-avec-blackrock\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/ggba.swiss\/fr\/oculis-obtient-jusqua-chf-100-millions-dans-le-cadre-dun-pret-avec-blackrock\/#primaryimage","url":"https:\/\/ggba.swiss\/app\/uploads\/2025\/08\/Oculis-Eye-Care-1180x811-1.jpg","contentUrl":"https:\/\/ggba.swiss\/app\/uploads\/2025\/08\/Oculis-Eye-Care-1180x811-1.jpg","width":1180,"height":811,"caption":"Le portefeuille de produits d\u2019Oculis propose des th\u00e9rapies non invasives et transformatrices aux patients souffrant de pathologies ophtalmiques et neuro-ophtalmiques pour lesquelles les options de traitement sont limit\u00e9es."},{"@type":"BreadcrumbList","@id":"https:\/\/ggba.swiss\/fr\/oculis-obtient-jusqua-chf-100-millions-dans-le-cadre-dun-pret-avec-blackrock\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ggba.swiss\/fr\/"},{"@type":"ListItem","position":2,"name":"Oculis obtient jusqu\u2019\u00e0 CHF 100 millions dans le cadre d\u2019un pr\u00eat avec BlackRock"}]},{"@type":"WebSite","@id":"https:\/\/staging.ggba.swiss\/en\/#website","url":"https:\/\/staging.ggba.swiss\/en\/","name":"Greater Geneva Bern area","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Person","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41","name":"Pierre-Yves Oehrli","url":"https:\/\/ggba.swiss\/fr\/author\/pierre-yves-oehrli\/"}]}},"_links":{"self":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/34809","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/comments?post=34809"}],"version-history":[{"count":1,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/34809\/revisions"}],"predecessor-version":[{"id":34811,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/34809\/revisions\/34811"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/media\/34806"}],"wp:attachment":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/media?parent=34809"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/categories?post=34809"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/tags?post=34809"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}